India · Delayed Price · Currency is INR Sun Pharma Advanced Research Company Company Description
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally.
It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial.
In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials.
The company was incorporated in 2006 and is based in Mumbai, India.
| Country | India |
| Founded | 2006 |
| Industry | Pharmaceutical Preparations |
| Employees | 316 |
| CEO | Anilkumar Raghavan |
Contact Details
Address: 17/B, Mahal Industrial Estate Mumbai, 400093 India | |
| Phone | 91 22 6645 5645 |
| Website | sparc.life |
Stock Details
| Ticker Symbol | 532872 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anilkumar Raghavan | Chief Executive Officer |
| Anup Rathi | Chief Financial Officer |
| Nitin Dharmadhikari | Chief Operating Officer |
| Jaydeep Issrani | Head of Investor Relations |